Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 12;20(1):90.
doi: 10.1186/s13024-025-00879-0.

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

Jingfeng Liang #  1   2 , Rongzhen Li #  3 , Garry Wong  3 , Xiaobing Huang  4
Affiliations
Review

Lewy body dementia: exploring biomarkers and pathogenic interactions of amyloid β, tau, and α-synuclein

Jingfeng Liang et al. Mol Neurodegener. .

Abstract

Lewy body dementia (LBD) is a neurodegenerative disorder characterized by a combination of progressive dementia and spontaneous parkinsonian symptoms. As the second most prevalent form of neurodegenerative dementia after Alzheimer’s disease (AD), LBD necessitates a deeper understanding of its pathogenesis to enable the development of targeted therapeutic interventions. While numerous reviews focus on documenting the clinical manifestations and therapeutic modalities for LBD, animal models provide valuable insights into the underlying mechanisms and potential therapeutic strategies. In this review, we systematically analyze the hallmarks of LBD pathogenesis, genetic risk factors, clinical features, and treatment strategies. Importantly, we emphasize and critically evaluate the pivotal role of animal models in LBD research in advancing our understanding of this disorder, offering a comprehensive framework to elucidate the interactions among misfolded proteins and their role in LBD pathogenesis. Our review proposes new directions for LBD therapeutic management and facilitates the development of innovative pharmacological interventions.

Keywords: Amyloid β; Dementia with Lewy bodies; Lewy body dementia; Parkinson’s disease dementia; Tau; Α-synuclein.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable. Consent for publication: Not applicable. Competing interests: The authors declare that there are no competing interests.

Figures

Fig. 1
Fig. 1
The pathogenesis hallmarks of LBD
Fig. 2
Fig. 2
Genetic risk factors contribute to the pathogenesis of LBD
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Stevens T, Livingston G, Kitchen G, Manela M, Walker Z, Katona C. Islington study of dementia subtypes in the community. Br J Psychiatry. 2002;180:270–6. - PubMed
    1. Rahkonen T, Eloniemi-Sulkava U, Rissanen S, Vatanen A, Viramo P, Sulkava R. Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older. J Neurol Neurosurg Psychiatry. 2003;74(6):720–4. - PMC - PubMed
    1. Kosaka K, Yoshimura M, Ikeda K, Budka H. Diffuse type of Lewy body disease: progressive dementia with abundant cortical Lewy bodies and senile changes of varying degree–a new disease? Clin Neuropathol. 1984;3(5):185–92. - PubMed
    1. Goedert M, Spillantini MG, Del Tredici K, Braak H. 100 years of Lewy pathology. Nat Rev Neurol. 2013;9(1):13–24. - PubMed
    1. Matsui Y, Tanizaki Y, Arima H, Yonemoto K, Doi Y, Ninomiya T, et al. Incidence and survival of dementia in a general population of Japanese elderly: the Hisayama study. J Neurol Neurosurg Psychiatry. 2009;80(4):366–70. - PubMed

LinkOut - more resources